Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02828644 · ClinicalTrials.gov registry record · NA

Software Treatment for Actively Reducing Severity of ADHD - Follow Up

A NA study of Attention Deficit Disorder With Hyperactivity, sponsored by Akili Interactive Labs.

Completed
Registry status
NA
Development phase
175
Enrollment target
15
Study locations

NCT02828644: Completed NA study of Attention Deficit Disorder With Hyperactivity, sponsored by Akili Interactive Labs.

NCT02828644 is a NA study of Attention Deficit Disorder With Hyperactivity that has completed, run by Akili Interactive Labs. The registered enrollment target is 175 participants, below the 346-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (49% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02828644, a NA study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Akili Interactive Labs.

COMPLETED
Registry status
NA
Development phase
175 participants
Enrollment target
15
Study locations

Study Summary

This is an exploratory study to assess potential maintenance of clinical benefit (cognition and symptoms) following 4 weeks of at-home digital therapy in ADHD children.

Primary Outcome

TOVA API is a comparison of the subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. The API is calculated from variability, response time, and d' (D Prime) using the following formula: API = Response Time Z score (Half 1) + d' Z score (Half 2) + Variability Z score (Total) + 1.80 where Response Time is the average time it takes to respond correctly to a target, d' score is a response discriminability score reflecting the ratio

Interventions

  • DEVICE EVO

Study Locations (15)

Florida

  • Florida Clinical Research Center, LLC - Bradenton
  • Florida Clinical Research Center, LLC - Bradenton
  • Meridien Research - Bradenton
  • Florida Clinical Research Center - Maitland

North Carolina

  • Duke Child and Family Study Center - Durham
  • Duke University - Durham
  • The Neuropsychiatric Clinic at Carolina Partners - Raleigh

California

  • Avida, Inc. - Newport Beach
  • University of California Davis MIND Institute - Sacramento

Arizona

  • Melmed Center - Scottsdale

Massachusetts

  • South Shore Psychiatric Services - Marshfield

Missouri

  • Midwest Research Group - Saint Charles

Nevada

  • Center for Psychiatry and Behavioral Medicine - Las Vegas

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2016-08
Est. Completion 2018-02
Phase NA
Akili Interactive Labs

13 total trials

What the finished NCT02828644 record still lists

NCT02828644 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 346-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (49% lower).

The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 1 intervention - of which EVO is the first listed.

NCT02828644 lists 15 locations in 9 states (Florida, North Carolina, California).

Frequently Asked Questions

What is clinical trial NCT02828644 about?

NCT02828644 is a clinical study titled "Software Treatment for Actively Reducing Severity of ADHD - Follow Up". This is an exploratory study to assess potential maintenance of clinical benefit (cognition and symptoms) following 4 weeks of at-home digital therapy in ADHD children.

What is the current status of trial NCT02828644?

This trial is currently completed. It is a NA study. The enrollment target is 175 participants. The study started on 2016-08. Estimated completion is 2018-02.

What conditions does trial NCT02828644 study?

This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.

What interventions are being tested in trial NCT02828644?

The interventions under investigation include: EVO (DEVICE).

Who is sponsoring clinical trial NCT02828644?

This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02828644 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Disorder With Hyperactivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02828644's enrollment target sits among peer trials

175 7th of 20 higher than 14 of 20 other Attention Deficit Disorder With Hyperactivity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02828644, the US trial registry maintained by the National Library of Medicine. NCT02828644 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.